Company Description
Expert.ai S.p.A., an artificial intelligence (AI) platform company, develops and sells cognitive computing software products based on AI algorithms to read and understand written language worldwide.
The company offers expert.ai Platform that captures the strategic value of language data; expert.ai Answers, a customer support automation software that allows human like interaction between customers and internal staff, using the language of business and users; expert.ai Discover, a text analytics, and extraction and categorization software; expert.ai for Insurance that automate insurance claims management with natural language understanding; and expert.ai for Life Sciences to mimic the human like comprehension of scientific content, such as publications, patents, clinical trials, or medical reports.
It serves the banking and insurance, public administration, life science and pharma, oil and gas, media and publishing, and telecom and utilities industries, as well as defense, and intelligence and law enforcement industries.
Expert.ai S.p.A. has a strategic partnership agreement with WealthIntel Inc. to facilitate innovations in natural language and text analytics.
The company was formerly known as Expert System S.p.A. and changed its name to Expert.ai S.p.A. in May 2021.
Expert.ai S.p.A. was founded in 1989 and is headquartered in Modena, Italy.
| Country | Italy |
| Founded | 1989 |
| IPO Date | Oct 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | David Hallett |
Contact Details
Address: Via Virgilio 56/Q Modena, 41123 Italy | |
| Phone | 39 059 894011 |
| Website | expert.ai |
Stock Details
| Ticker Symbol | EXAI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $22.00 |
| CIK Code | 0001865408 |
| CUSIP Number | 30223G102 |
| ISIN Number | US30223G1022 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Hallett Ph.D. | Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer and Executive Director |
| Ben R. Taylor | Chief Financial Officer, Chief Strategy Officer and Executive Director |
| Dr. John P. Overington Ph.D. | Chief Technology Officer |
| Sara Sherman | Vice President of Investor Relations |
| Dan Ireland | Executive Vice President of Legal and Company Secretary |
| Parker Moss | Executive Vice President of Corporate Development |
| Caroline Rowland | Chief People Officer |
| Richard Law | Chief Business Officer |
| Nikolaus Krall | Executive Vice President of Precision Medicine |
| Dr. Marie-Louise Helena Fjallskog M.D., Ph.D. | Interim Chief Medical Officer and Clinical Development Lead |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 20, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 25-NSE | Filing |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Nov 6, 2024 | 6-K | Report of foreign issuer |
| Oct 24, 2024 | 144 | Filing |
| Oct 10, 2024 | 6-K | Report of foreign issuer |